Karachi, Highnoon Laboratories Limited informed Pakistan Stock Exchange that Annual Report of the Company for the year ended December 31, 2018 have been transmitted through PUCARS and is also available on Company’s website.
Highnoon Laboratories Limited was incorporated in March 1984 as a
Private Limited Company in the historical and cultural city of Lahore,
Pakistan. It became Public Limited Company in 1995 and the shares of the
Company are listed on all the stock exchanges of Pakistan.
Right from its inception, alliance with some of the best-known research houses
of the global pharmaceutical industry were forged by Highnoon. These alliances
coupled with aggressive yet ethical marketing activities enabled Highnoon to
become the first pharmaceutical Company of Pakistan origin to be in the top
twenty league of Pakistan pharmaceutical industry.
Equally responsible for Highnoon’s success is the unshakeable consumer
confidence that the Company has been able to build on the quality of its
products manufactured in its ISO 9001:2008 approved facility.
Highnoon is continuously re-aligning its portfolio to ensure that it is able to
harness opportunities. At the same time, the Company is modernizing its plant,
by investing in new equipment and technology to upgrade its manufacturing
facilities to comply with ‘Current Good Manufacturing Practices (cGMP)’.
Highnoon’s therapeutic focus in Cardiology, Gastroenterology, Respiratory and
Diabetics has led to the development of franchises, which are now the most
admired in the healthcare industry. Highnoon has since then, marched ahead
introducing state of the art products and setting new trends.
The symbol “HINOON” is being used by the stock exchange for the shares of
Highnoon Laboratories Limited.
